



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE


Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

## STOCK INFORMATION

### CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$13.70</b>
Change (%)	▼ 0.2 (1.44%)
Volume	422,335
52 Week Low	\$10.80
Market Cap	\$703,620,862
Rolling EPS	-2.25
PE Ratio	N/A
Shares Outstanding	51,359,187

Data as of 10/20/17 4:00 p.m. ET



## RECENT NEWS & UPCOMING EVENTS

09/07/17

[Coherus BioSciences Provides Update on '619 IPR Institution Decision](#)

09/01/17

[Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September](#)

08/28/17

[Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 \(Humira® Biosimilar Candidate\) versus European Marketed Humira in Healthy Subjects](#)

There are currently no events scheduled.

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
10/16/17	<u>EFFECT</u>
09/22/17	<u>S-3</u>
09/07/17	<u>8-K</u>
09/06/17	<u>SC 13D/A</u>

## CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.